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1 | WHY DO WE NEED TO INDIVIDUALIZE
PERIODONTAL CARE?
Beginning in the late 1960s and extending through to the mid-
1980s, several impressive clinical studies successfully simplified the
causation of gingivitis and periodontitis to establish a primary role
for bacterial accumulations on the teeth.1-4 These early studies
focused on initiation and reversal of gingivitis and demonstrated that
the basic concept of a critical role for bacterial accumulations in peri-
odontitis held up in dogs and appeared to be similar in populations
such as tea workers in Sri Lanka5-7 (Figure 1).
The key observations of a primary “cause” of gingivitis and peri-
odontitis were followed by landmark longitudinal studies at the
University of Michigan and the University of Gothenburg which
established core principles in prevention and treatment of periodon-
titis.
The clinical experimental gingivitis studies in dental students and
the experimental periodontitis studies in dogs strongly supported the
general concept that bacterial accumulations on the teeth pre-
dictably led to gingivitis and, if untreated, progressed to periodonti-
tis. The details of some of those studies and observations by many
clinicians did not, however, support the concept that periodontitis
was a simple linear relationship between bacterial accumulations and
initiation and severity of periodontal disease. In spite of important
gaps or contradictions in the evidence, the basic message was that
we could predictably prevent and treat periodontitis by a combina-
tion of professional and patient-directed approaches to bacterial
control. This was a major advance over the clinical concepts in the
preceding period that resulted in conflicting approaches to the treat-
ment of periodontitis and therefore less predictability in outcomes.
Unfortunately, we communicated to many dentists, hygienists,
and patients an implicit extension of the new concept which sug-
gested that the severity of periodontitis was a simple function of the
magnitude of bacterial accumulations and the time of exposure. The
unspoken corollary was that, given bacterial exposure, all individuals
are equally susceptible to periodontitis, and if treated according to
the proven principles from the longitudinal studies patients should
respond in a predictable manner. If those concepts are correct, there
is no clear value to stratifying a patient’s risk for developing peri-
odontitis or responding predictably to therapy.
Key point: Evidence indicates that some individuals have
greater risk for developing severe periodontitis and some
do not respond predictably to standard treatment princi-
ples and maintenance care
Two major exceptions emerged but failed to dissuade clinicians from
the concepts that everyone was equally susceptible and that every-
one responded predictably to bacterial reduction therapy. The first
exception was that among populations with no routine oral hygiene
or professional dental care, most individuals developed only mild-to-
localized moderate periodontitis.8,9 The evidence that emerged from
Sri Lanka over time indicated that despite extended exposure to sub-
stantial levels of bacteria and calculus on the teeth, only a small per-
centage of the population progressed to severe generalized
periodontitis (Figure 2). The second exception was that among
patients treated and maintained appropriately for advanced peri-
odontitis, approximately 20%-25% continued to have disease pro-
gression and lose teeth,10-12 and in some studies the disease
progression during post-treatment maintenance care was associated
with a small number of patient-level risk factors.13-18 In addition,
when adults, most of whom had participated in a standardized pre-
vention program, were reevaluated after 10 years, 12.3% had lost
multiple teeth because of periodontitis.19 Recent studies of various
designs appear to support earlier observations that, as a result of
specific risk factors, some individuals have increased risk for severe
periodontitis or for increased tooth loss or periodontitis progres-
sion.20-25 Those studies and observations by many clinical periodon-
tists are the primary rationale for individualizing risk for
periodontitis.
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Chronic complex diseases have variable presentations among
affected patients and probably reflect the cumulative biological result
of multiple factors that modify various components of the pathophysi-
ology of the disease. Progressive tooth loss in a subset of patients
treated for periodontitis is consistent with general concepts of the
clinically meaningful role of individual differences in chronic diseases.
It is all about prevention of severe disease and complications?
Leroy Hood’s “P4 Medicine” has succinctly captured not only the
overall vision of precision healthcare but emphasizes the critical role
of prevention in precision medicine as an essential strategy for con-
trolling chronic diseases.26-28
P4 medicine refers to programs that are:
• Personalized. Identifying on which disease path an individual is
traveling as they age.
• Predictive. Identifying the disease path before an individual has
developed a severe form of the disease or a major complication
of the disease.
• Preventive. If one can intervene early at the predictive stage to
modify the disease path there is an opportunity to extend the
time until the individual develops sufficient disease severity and
complications that there is compression of the individual’s mor-
bidity.
• Participatory. Many chronic diseases require patient participation
to manage the disease successfully. Both prevention and treat-
ment of periodontitis have a participatory element that is sub-
stantial, if not deterministic.
2 | WHAT DO WE MEAN BY “ INDIVIDUAL
RISK FOR PERIODONTITIS”?
Key point: No facts about the future, only probabilities:
Risk factors are how we estimate an individual’s proba-
bility for future disease progression and response to
standard therapies.
F IGURE 2 In studies of populations with minimal to no oral hygiene and substantial accumulations of bacteria on the teeth, most
individuals developed mild periodontitis with localized moderate disease (green circles). A small group developed only mild periodontitis (blue
circles), and a smaller group developed severe generalized periodontitis (red circles)8,9
F IGURE 1 Clinical research beginning in the 1960s led to a simple concept that rapidly became the dominant approach to prevent and
treat gingivitis and periodontitis. The concept of bacterial plaque causation indicated that bacterial accumulations on the teeth, if not removed,
initiated gingivitis which transitioned into periodontitis. The concept also suggested that continued exposure to bacteria over time would result
in severe periodontitis
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Physicians and dentists have long used personalized
approaches to manage their patients. The new era of precision
medicine, often referred to as personalized, individualized, or
stratified medicine, attempts to take advantage of molecular signa-
tures or individual biomarkers combined with traditional risk fac-
tors to predict, more clearly, the course of one’s disease or to
guide choice of therapies.
Clinical use of precision medicine in oncology and rare disorders
has greatly benefited patients through new drug development and
better drug outcomes. For example, there are 2 main histologic sub-
types of lung cancer which result in more than 150,000 deaths
annually in the USA. In the past 10 years, subsets of non-small cell
lung cancer have been identified based on mutations in key control
points of multiple oncogenes. Of the 15 gene mutations identified to
date in non-small cell lung cancer, drugs are currently approved for
8 .29 At present, much of the focus in oncology is on matching the
most appropriate drug to the causative mutation to stop disease pro-
gression and increase survival.
Use of precision medicine in oncology and rare diseases is a
valuable model but it does not translate well for chronic diseases.
In chronic diseases many of the strongest risk factors are environ-
mental or acquired, such as smoking, diet, and obesity. The clinical
features of a chronic disease phenotype are often the result of
multiple biological pathways, each of which includes multiple
genes and environmental factors that interact to regulate the
pathway and ultimately the clinically observable expression of dis-
ease. For common chronic diseases, the biology is not as deter-
ministic as in oncology and rare diseases, and the clinical
expression is a probabilistic summation of the key pathways and
their components.30 The net result of the complexity of chronic
disease is not 8 or 15 molecular subtypes of the disease that
define treatment choice and response, as in non-small cell lung
cancer, but rather a small number of clinical disease patterns that
represent different trajectories over time and different responsive-
ness to standard interventions.
These are probably the result of many molecular subtypes that
produce a few clinical disease patterns or phenotypes. Individuals
with observed variations in clinical presentation, including age of
onset, severity and extent of disease relative to age, and predictabil-
ity of clinical response to conventional periodontal therapy, are unli-
kely to have differences in the actual pathophysiology of
periodontitis in the periodontal tissues.
One might conclude that the functional changes in disease-asso-
ciated tissues compared with health-associated tissues represent
basically the same pathophysiology, regardless of the clinical differ-
ences among patients. If that is the case, then individuals with varia-
tions in clinical disease probably have the same disease. So, how do
we explain the clinical differences we see? Based on current knowl-
edge, individual differences in periodontitis progression appear to be
explainable by biological modifiers, including: environmental factors
(such as smoking); genetic variations that modify the immune-inflam-
matory response, alter wound healing, and influence bone and con-
nective tissue remodeling; or an acquired disease (such as
uncontrolled type 2 diabetes) that influences the individual’s host
response to bacterial challenge. The net result of one or more of
these modifiers is a change in the rate of certain physiological path-
ways to influence the biological response to the bacterial challenge
and reduction of that challenge.
The chronic diseases often display disease heterogeneity,31,32
meaning that different pathways can lead to the same clinical pheno-
type (ie, “many to one”), and also genetic heterogeneity, in which
one node in a pathway may lead to multiple diseases (ie, “one to
many”).33 The latter phenomenon is evident when the same drug
(eg, a tumor necrosis factor alpha blocker) shows clinical value in
treatment of multiple complex chronic diseases.
To address the question of whether it is possible to identify indi-
vidual risk for periodontitis, and perhaps more importantly if it is
practical to do so, one must start with a set of risk factors that have
been individually validated. As those risk factors probably influence
one or more pathways, and we have multiple risk factors for a
chronic disease such as severe chronic periodontitis, we must also
have a mechanism to stratify patients using combinations of multiple
risk factors (Box 1).
This involves a long and demanding process that requires 3 suc-
cessive steps: step 1, identify/discover potential risk factors; step 2,
clinically validate putative risk factors; and, step 3, demonstrate clini-
cal utility attributable to the use of specific risk factors. As the pri-
mary objective of this paper is to address the clinical utility question
of whether we can currently identify individual risk for periodontitis,
it is out of its scope to review the evidence for discovery and clinical
validation of potential risk factors. Fortunately, there are outstanding
recent publications reviewing evidence for the major risk factors for
periodontitis34-39 and I will accept some of those factors as a start-
ing point for this discussion of whether we can use existing clinical
utility evidence, albeit very limited, to identify individual risk for
periodontitis.
2.1 | Step 1: discovery of potential risk factors for
periodontitis
Can we identify specific factors that are associated with patient dif-
ferences in clinical signs of periodontitis, progression or severity,
response to treatment, or systemic implications or periodontitis?
BOX 1 Identifying individual risk for periodontitis: start
by explicitly defining the goal
1. Risk for this patient developing periodontitis?
2. Risk for this patient’s periodontitis progressing to moder-
ate to severe generalized periodontitis?
3. Risk for this patient having a less predictable response
to standard periodontal therapies and maintenance care?
4. Risk for this patient’s periodontitis having implications
for systemic disease?
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2.2 | Step 2: validity
Two types of medical test validity are important: analytical validity
and clinical validity, discussed in further detail below.
• Analytical validity refers to the accuracy with which a trait can be
identified and quantified. This can refer to clinical parameters and
the reproducibility of measurements among different clinical
examiners or the same examiner over time. It is important to
assure and make publicly available the analytical validity of bio-
chemical, genetic, and physiologic assays, whether single analyte
assays or large multiplexed assays, for which very different levels
of expertise may exist across multiple laboratories and diverse
assay systems. Analytical validity also includes validation of data
management systems that are used to collect, analyze, and report
data. In recent years analytical validity problems with -omics data
have been reported as a result of failure to assure analytical and
clinical validity before clinical application of gene expression
patterns.40,41
• Clinical validity describes the accuracy of a specific risk factor to
influence a particular clinical outcome. For example, is there evi-
dence that a specific risk factor changes the biology in a manner
that is relevant to severity/progression of periodontitis? Is the
risk factor consistently associated with chronic periodontitis
severity or progression?
A risk factor is often defined from an epidemiological perspective
as an exposure that is associated with a particular clinical outcome,42
whether or not the relationship is causal. As periodontitis initiation
or progression must be observed over many years, clinical validity is
often based on multiple confirming association studies. Randomized
controlled intervention studies directed at modifying a specific risk
factor provide the most convincing evidence of a risk factor’s causal-
ity, but such studies are difficult to perform in periodontal disease,
and few exist. Fortunately, there are well-described criteria for
assessing the likelihood of causality of a disease-associated risk fac-
tor.43 The criteria for clinical validity of risk factors in periodontal
disease must start with consistent association of the factor with
well-defined periodontal outcomes in appropriate populations. For
some clinical uses we may be happy to have a marker that helps
predict a maintenance patient’s future likelihood of progression with-
out concern of whether the marker is causal; for example, a certain
level of bleeding on probing at multiple visits is a very good predic-
tor of future progression, even though bleeding itself is not causing
the progression.44,45
However, risk factors that are “causal” provide an opportunity
to target the risk factor to prevent or treat disease. Given consis-
tent associations of a risk factor with a periodontitis phenotype,
one’s confidence in the causality of the factor increases based on
the following: (i) biological plausibility; (ii) biological gradient or
dose-response relationship; (iii) temporal relationship (ie, does
exposure to a putative causal factor precede disease phenotype?);
and (iv) experimental evidence that tests a causal relationship
hypothesis.43 A risk factor with a consistent association and evi-
dence to support causality is more likely to influence a particular
clinical outcome.
As most individuals exposed to bacterial accumulations on the
proximal surfaces of their teeth for long periods of time will develop
mild periodontitis with a few localized sites of moderate periodonti-
tis, the primary importance of risk factors and individual risk for peri-
odontitis relates to a more severe phenotype. Individual risk for
periodontitis is important to help identify patients who are more
likely to: (i) develop moderate-to-severe generalized periodontitis; (ii)
exhibit clinical progression in the face of standard periodontal ther-
apy; and (iii) have periodontitis that influences a development or
treatment outcomes of systemic diseases.
2.3 | Step 3: clinical utility refers to the likelihood
that information about a specific risk factor or set of
risk factors will lead to actions that improve health
outcomes
Key point: Risk factor clinical utility for a complex
chronic disease such as periodontitis: Individualizing risk
generally requires multiple risk factors and a way to inte-
grate the influence of multiple risk factors in a single
individual.
Clinical utility requires the application of risk factors to classify
individuals into discrete groups in order to guide disease prevention or
intervention. Many factors with very strong association data may not
make good classifiers.46,47 Garcia et al48,49 have provided excellent
discussions of the limited predictive value for some powerful risk fac-
tors in multiple diseases, and they also illustrate the challenges of pre-
dicting risk for an individual patient, which of course is critical to
clinical value. In addition, Garcia et al48,49 note that many risk factors
must be included to predict the majority of risk for death attributable
to coronary artery disease. Although an individual risk factor may not
be impressive in predicting the total population risk of a specific com-
plex disease, some single risk factors (eg, blood cholesterol) have pro-
ven to be very valuable for guiding use of statins to achieve low levels
of low density lipoprotein cholesterol, and thereby reducing cardiovas-
cular disease events, including myocardial infarctions and deaths.
Although many patients are at risk for cardiovascular events as a
result of other risk factors, an initial set of risk factors can be used
to guide treatment for an important segment of the at-risk popula-
tion. Such an approach also adds value by determining residual risk
in some patients after treatment based on the strongest risk factors
initially identified. For example, in a randomized controlled clinical
trial of more than 15,000 overtly healthy adults with no prior history
of cardiovascular disease and “normal” low density lipoprotein
cholesterol levels (<130 mg/dL), the risk factor of elevated systemic
inflammation (≥2 mg/L of C-reactive protein) was used to target
individuals who might benefit from high dose statins that modestly
reduce systemic inflammation. This was an effective strategy and
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demonstrated that high dose statins lowered even “health-asso-
ciated” levels of low density lipoprotein cholesterol and inflammation
to prevent the first cardiovascular events, achieving a 54% reduction
in risk of heart attack, based on actual reduction of clinical events
compared with placebo.50 In that intervention study based on suc-
cessfully reducing the 2 strongest risk factors for cardiovascular
events, a third-level risk factor, lipoprotein(a), was identified as a
residual risk factor that, in spite of lowering already low levels of
low density lipoprotein-cholesterol and systemic inflammation, this
patient group needed a different therapeutic approach now identi-
fied by a third risk factor. Multiple new drugs targeting this third risk
factor, lipoprotein(a) are in late stage development.51
In periodontitis, there are few studies that have been explicitly
designed to test the hypothesis that risk stratification with specific
factors, such as smoking, type 2 diabetes, obesity, genetics, or
others, influence periodontal outcomes of therapy or preventive
care.21,52-54 If biases are properly considered and adequate sample
sizes are available, it is possible, in some situations, to use large ret-
rospective databases to ask prospective questions relative to the
influence of patient stratification on disease prevention or treatment
outcomes. This “prospective-retrospective” study design is being
used routinely in the effort to discover and validate biomarkers to
guide the use of new drugs that are expensive and have the poten-
tial for serious adverse drug events.55
2.3.1 | Risk factors should be moved to the clinical
utility stage as early as possible
With common, but complex, chronic diseases, our goal should be to
improve clinical management of the disease. As the decision analysis
gurus teach us, there are no facts about the future, only probabili-
ties. Prospective pilot studies allow us to unravel the relative impor-
tance of multiple factors in critical disease endpoints, such as
disease progression and response to specific interventions.
2.3.2 | What are the practical elements required to
get to clinical value?
Clinical utility indicates that there is a difference in the disease that is
sufficient to influence the disease progression/severity (and therefore
tooth loss and replacement), response to treatment, and systemic
implications. The key question to be studied for clinical utility there-
fore goes beyond a simple disease association. The clinical utility ques-
tion often has 3 parts: (i) if a specific patient is in one specific risk
classification and (ii) is treated with different well-defined approaches,
(iii) what is the actual observed frequency of a specific outcome?
2.4 | Individualized periodontal medicine starts with
stratifying patients into specific buckets
Although individualized periodontal medicine suggests that an indi-
vidual patient may have a unique biological fingerprint and therefore
receive a unique therapy, this is not the reality in most chronic
diseases. Individualizing risk must begin with criteria that allow every
patient to be stratified into discrete and nonoverlapping categories
(Figure 3). Stratification is often a key part of the clinical utility
phase because it must build on learnings during the discovery phase.
Risk factors that are highly significant during the discovery phase
may not be informative in stratifying individuals for clinical pur-
poses.46,47 Complex diseases do involve thousands of interacting
factors that probably could define a unique phenotype for every
individual. Biological pathways that influence a complex disease in a
specific individual interact, but some nodes in a pathway are more
important than others and have leverage to change the disease out-
come.30 As with most chronic diseases,56 the evidence suggests that
individuals with periodontitis follow a small number of clinical paths
that describe progression and severity patterns in the population.
Similarly for periodontitis patients treated using standard principles,
70%-80% of patients respond predictably and favorably10,12 with the
others either not complying with regular maintenance care or being
enriched with a small number of risk factors.13-18,23,24,57-59
2.5 | Stratification may be simple or complex
Current regeneration technology offers impressive opportunities to
enhance supporting periodontal tissues and prolong retention of
teeth. Predictable and useful periodontal tissue regeneration requires
stratification of patients and sites to provide the most effective
long-term outcomes.60 Such stratification may use simple or complex
patterns. Many parameters that are highly significant predictors of
outcomes in large case-control studies may not be good “classi-
fiers”.46,47 The important aspect of good classifiers for practical clini-
cal use is that specific parameters can be used separately or
combined into a well-defined pattern that classifies individual
patients into distinct categories that are of clinical value.
2.5.1 | Simple stratification
Recombinant human platelet-derived growth factor BB homodimer
may provide very good long-term regenerative success in certain
sites and for certain patients. A group of clinical investigators
reported good long-term advantages over the scaffold alone, but
only for smokers61 (Figure 4).
Although single risk factors are unlikely to be highly informative
in observational studies of complex diseases, it is not uncommon to
see single risk factors stratify responses to therapy or influence pro-
gression of complex diseases. For example, in a clinical trial of 7,018
high-risk cardiovascular disease patients randomized to the American
Heart Association low-fat diet or the Mediterranean diet and fol-
lowed for more than 4 years, a single genetic factor (TCF7L2)
explained a 3-fold increase in stroke for individuals on the low-fat
diet.62 In addition, the Mediterranean diet essentially eliminated all
added risk for strokes attributable to the TCF7L2 genetic effect.
Other studies have reported that single genes, unrelated to drug
metabolism, can have a major effect on clinical outcomes of drug
therapy for chronic diseases.63,64 To demonstrate clinical value in
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patient stratification, we should try as much as possible to ask a
question about disease progression over time or response to treat-
ment over time in prospective studies.
Not only do questions of disease progression and response to
treatment allow us to get close to clinical utility, we also avoid multiple
challenges inherent to case-control studies of periodontal disease.
Two of the major challenges of periodontitis in observational studies
are: (i) extraction of 6-8 teeth can convert a case of moderate-to-
severe generalized periodontitis into a case of mild disease with 20
remaining teeth; and (ii) multiple factors, such as smoking, appear to
influence the initiation and progression of periodontitis.65-67 The first
challenge produces an incorrect classification of the patient. If one is
studying genetic factors in severe periodontitis, false positives may be
present when a specific genetic factor is present but extractions have
produced a patient classified as having mild periodontitis. The second
challenge produces a dilution of the effect size of any single factor (ie,
“many roads lead to Rome”) and the statistical management of multiple
risk factors may mask their individual differences in terms of disease
phenotype and biology.37
Key point: How can one possibly combine multiple risk
factors to establish the net risk for a single individual?
In periodontal disease, one of the biggest challenges is how to
account for missing teeth in cross-sectional or case-control studies.
Prior history of periodontitis is strongly associated with future risk.
When there are multiple putative risk factors, one should start with
a few classic risk factors, such as smoking and type 2 diabetes. Initial
studies should demonstrate significant association between the core
set of risk factors and sequentially add exploratory or novel risk fac-
tors to assess whether, for a specific phenotype, the exploratory risk
factor adds value to classic risk factors in this disease. Perhaps most
importantly some risk factors modify the effect of classic risk factors
on the disease outcome.24,59,68,69
F IGURE 3 The first and essential step in individualizing risk for periodontitis, and ultimately individualizing prevention and treatment, is
having predefined criteria that stratify every patient into well-defined categories that are mutually exclusive
F IGURE 4 Bone regeneration in certain types of periodontal defects was enhanced by the use of recombinant human platelet-derived
growth factor BB homodimer (rhPDGF-BB), but the substantial long-term regenerative potential was observed primarily in smokers, as noted
by the amount of bone gain in the smokers treated with platelet-derived growth factor (blue solid line) compared with the smokers who
received the scaffold alone (green solid line). The linear bone gain figure is reproduced with permission from Nevins et al.61 The clinical and
radiographic images are courtesy of Professor William Giannobile, University of Michigan
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2.5.2 | Complex stratification
Practical application of a risk factor model that includes multiple risk
factors is challenging, but essential for clinical utility for 2 primary
reasons:
• It recognizes that for complex diseases there are multiple physio-
logical pathways that can lead to disease. To focus on only one
of those pathways may result in many false negatives, as other
factors may lead to the same phenotype.
• Multiple risk factors may be additive, and in some cases condi-
tional. For example, the Framingham Risk Score estimates an indi-
vidual’s 10-year risk for developing diagnosable coronary artery
disease. Translation of the score into risk depends on an age- and
gender-based algorithm that combines multiple factors, such as
total cholesterol, blood pressure, and smoking. One can input a
range of values for the risk factors and quickly see that using a
single factor accounts for a limited part of the total risk for some-
one of a specific age and gender.70 In addition, some risk factors,
such as lipoprotein(a), that have been determined to be causal for
coronary artery disease,71 do not appear to result in major cardio-
vascular disease events unless there is a second factor present
that amplifies the inflammation.69
The Periodontal Risk Assessment system, as developed and
described by Lang & Tonetti 14,17,72 and shown in Figure 5, is one
example of tools that integrate multiple risk factors in assessment of
periodontitis. The Periodontal Risk Assessment system allows the
identification of individuals who may be at risk for disease
progression as a result of multiple known and unknown factors. The
risk may or may not involve an interaction between risk factors, but
one of the strengths of the system is that it acknowledges a broad
range of risk factors without forcing the system to include all fac-
tors.
More complex interpretations of multiple risk factors in a predic-
tion model, of course, depend on having a broad range of data that
allow validation of the value of the tool for different patients in dif-
ferent scenarios.
It is reasonable to use selected risk factors together in a simple
additive model (ie, a patient with any 2 risk factors is assumed to be
at greater risk than a patient with no or only or 1 risk factor). Such
models may use regression data to assign a quantitative magnitude
of effect to each risk factor, or risk factors can be assumed to be of
equal effect. In simple multifactorial risk models, it is important to
predefine the risk interpretation of different possible combinations.21
If adequate databases are available with well-defined progression
data or clinical event data, one may evaluate the impact of adding
new risk factors to a standard risk model by means of calculating a
“net reclassification index”73-75 which determines whether the new
risk factor changes the risk classification of specific individuals to a
clinically meaningful extent.
For many years some investigators have studied multiple aspects
of chronic periodontitis with increasing attention to biomarker clus-
ters that stratify subsets of chronic periodontitis.76-79 Because com-
plex chronic diseases, by definition, involve multiple genes and
multiple environmental factors that interact with many permutations,
theoretically we may all be uniquely different at the molecular level.
The challenge becomes how to set the granularity to a level that is
F IGURE 5 Periodontal risk assessment
system, as defined by Lang and Tonetti14
in 2003. The graphical representation of
risk uses a spider web image in which each
axis of the web is a risk factor and each
increment from the center of the web
outward allows the clinician to indicate the
patient’s level of risk for each specific risk
factor. The visual image provides a clear
impression of a patient’s composite risk.
The figure is reprinted with permission
from Oral Health & Preventive Dentistry.14
BL, bone loss; BOP, bleeding on probing;
Envir., Environmental factors; Gen.,
genetics; PD, probing depth; Syst.,
systemic disease
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clinically meaningful. The challenge of translating the biological com-
plexity into actionable targets has been addressed recently, relative
to cardiovascular disease, where the use of loss- or gain-of-function
mouse models has implicated dozens of molecular targets as major
drivers of atherosclerotic cardiovascular disease, yet few of these
targets have been shown to be causal and to have value in prevent-
ing or treating clinical disease.30
The challenges are how to move from single parameter discovery
to the integration of multiple parameters and then to actual classifi-
cation of individual humans. That is ultimately what we are asked to
do when one changes the question from, “What are the major risk
factors for periodontitis?” to “How can we identify an individual’s
risk for progression or severity of chronic periodontitis?”
In recent years, some groups21,79 have explored various approaches
to stratifying individuals relative to chronic periodontal disease. As they
and others experienced, biological explorations of chronic periodontitis
using -omics approaches have not been greatly rewarding, perhaps in
large part because of inherent weaknesses of periodontal observational
databases for which a single phenotype is assumed.
Dr. Offenbacher and his colleagues used a large cross-sectional
database with periodontal data to identify a set of complex traits
based on prespecified parameters, such as microbial patterns defined
by 8 periodontal bacterial pathogens and the status of periodontal
inflammatory response as measured by interleukin-1beta levels in
gingival crevicular fluid.80 Six patterns were identified based on 2
biological characteristics, markers of specific microbial ecologies, and
periodontal levels of inflammation. These 6 biologically defined pat-
terns allowed each patient in the database to be matched to 1 of
the specific patterns. The team could then explore genetic differ-
ences among the 6 biologically defined complex traits. This approach
has multiple important advantages, for example: the biology defined
by a pattern has a narrowed search space relative to genetic influ-
ences, not unlike focusing on disease progression or response to
treatment; and every patient can be classified. Both of these study
characteristics are important to advance toward clinical utility
because the starting point for studying the potential value of individ-
ualized risk for periodontitis is being able to classify every patient
into a predefined category.
Offenbacher et al77 have recently advanced the stratification to
attempt to define clinical substructure in the disease to untangle
chronic periodontitis into multiple well-defined clinical classifications.
This again represents an important starting point to use the newly vali-
dated classifications to explore specific hypotheses about disease pro-
gression or different responses to periodontal therapy.
3 | USING CURRENT EVIDENCE TO
INDIVIDUALIZE RISK FOR PERIODONTITIS
The vast majority of individuals will develop periodontitis when
exposed to an undisturbed subgingival bacterial mass over time.
Observational studies indicate that most periodontitis will result in
mild disease with a few local sites with moderate disease, regardless
of the bacterial challenge.8,9 Evidence from interventional studies
supports a predictable periodontitis response to bacterial control in a
majority of patients.10,11,81-87 The challenge, as specialists, is to iden-
tify subsets of patients who respond differently to bacterial chal-
lenge and either express more severe periodontitis or do not
respond predictably to standard clinical approaches to periodontitis
prevention and treatment. Thus, periodontists need to conduct
research to define how to stratify patients, in order to identify those
who require a different approach to clinical management and to
develop clinical protocols for efficient prevention and treatment of
more complex cases.
3.1 | Clinical Scenario 1: primary prevention of
periodontitis at the population health level
If our goal is to reduce the prevalence of periodontitis among adults
in a specific population, this is a population health initiative that is in
part an access-to-care issue and an education issue. For example, in
the USA, epidemiological data indicate that periodontitis, and espe-
cially severe disease, is enriched in segments of the population
below twice the federal poverty line.20,88 The same enrichment for
severe periodontitis is seen in very targeted geographic locations in
the USA that are dominated by lower socio-economic and education
attainment.89 A second population that is enriched for severe peri-
odontitis, at least as represented by tooth loss, comprises individuals
who have good access to dental care through employee-based den-
tal insurance but do not see a dentist regularly for preventive care.21
3.1.1 | Using individual risk factor information to
focus periodontitis prevention messages
Beyond educating mothers, children and young adults about the
importance of oral hygiene and oral hygiene methods, we can start
to focus the messages on individual risks for periodontitis. Some of
the emphasis should be on the value of preventing periodontitis with
the individual risk role that smoking and uncontrolled type 2 dia-
betes plays in periodontitis severity and complications of tooth loss.
Although we are discussing a population health message, the
approach can include self-awareness messages of individual risk, and
the action message should encourage regular professional periodon-
tal assessments to identify and address periodontitis early and to
educate about personal care. The individual risk message helps to
personalize the risk and potential solutions for a patient’s individual
needs.
3.2 | Clinical Scenario 2: use of individual risk for
periodontitis to prevent moderate-to-severe
periodontitis in individuals with access to dental care
Routine primary preventive care to reduce the likelihood of peri-
odontitis, as has been taught to dentists, hygienists, and patients for
many years, is anchored by assumptions and expectations that are
correct for the majority of our patients but fail to manage those
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who are at greatest risk. This has been shown to be true even for
adult patients who have been managed according to the well-proven
“needs-related” approach to preventive dental care, as defined by
Axelsson et al.90,91
The current approach to primary preventive periodontal care in
general dentistry includes 2 faulty assumptions and one incorrect
expectation.
• The first faulty assumption is that all patients are equally suscep-
tible to periodontitis, and the clinical expression of periodontitis
results entirely from exposure to bacterial plaque over time.
• The second faulty assumption is that periodontitis progresses
slowly, so once a patient is identified with mild periodontitis,
standard protocols will predictably manage the disease. The treat-
ment approach generally used in such situations involves
repeated prophylaxis with scaling and root planing as indicated in
the isolated sites that show early periodontitis. Such approaches
may be augmented with targeted interproximal oral hygiene
instructions and local delivery of antimicrobials.
• The incorrect expectation of the primary prevention outcomes is
described above, and this is that a patient with early mild peri-
odontitis will respond predictably to the scaling and root planing
of the sites with localized mild disease. The current standard in
most dental offices throughout the world is that scaling and root
planing management of mild periodontitis rarely has a follow-up
visit to assess response of the patient. This, of course, is based
on the reality that most patients will in fact respond very pre-
dictably to such a therapeutic intervention.
4 | OPPORTUNITIES TO ADD CLINICAL
VALUE BY INDIVIDUALIZING RISK FOR
PERIODONTITIS
The curves shown in Figure 6 postulate what to expect in individu-
als who see a dentist regularly for routine preventive care. The
question is, “What can we expect to see in terms of periodontitis
progression to moderate-to-severe generalized periodontitis in
patients who are part of the regular dental care system?” There are
large dental insurance databases, managed dental care databases,
and nationwide epidemiology findings that can provide some
insights to answer this question, but we must acknowledge the lim-
itations. To some extent, the boundaries of periodontitis expression
may be seen in the studies of populations in Sri Lanka and Tanza-
nia with minimal to no personal oral cleaning and no professional
cleaning.8,9 Although not analogous to patients in routine dental
care in the USA, Europe, and Asia, the maximum disease boundary
may be a good disease stratification perspective as one envisions
applying such boundaries to individuals with access to routine den-
tal care.
Most patients (as shown by the blue line in Figure 6) will have
mild disease detected at some point and with appropriate preventive
care will develop predominantly mild periodontitis with a few
localized sites with moderate disease. The gray line is intended to
represent the 8%-10% of individuals who are on a different path.
The X and Y points on Figure 6 are on 2 different theoretical peri-
odontitis progression curves; yet, to the clinician, the periodontal
assessment is likely to appear the same. Based on current knowledge
of periodontitis, the age differences at the time of the first clinical
diagnosis of mild periodontitis are unlikely to be remarkable.
Although current evidence suggests that patients on the gray line
are enriched with a small set of clinically important risk factors, and
they may be noted by the clinician, there has not been sufficient evi-
dence to manage the cases differently, given the clinical findings of
mild periodontitis in both patients at their initial examination.
5 | PRIMARY PREVENTION AND
TREATMENT OF MILD PERIODONTITIS
Key point: Do we have evidence that for patients under
the routine care of dentists, individual risk assessment
adds value to guide primary periodontitis prevention or
treatment of mild periodontitis?
In many ways, this question is really asking the P4 medicine
question of whether we can predict which periodontally healthy
patients are more likely to be on the gray line than the blue line
(Figure 6) because the individual on the gray line is projected to
have clinically important progression of periodontitis, leading to
complications such as tooth loss. We already know that most
patients, even with only moderate oral hygiene, are likely to
develop only mild periodontitis with—at most—a few localized sites
of moderate disease. So, the problem in clinical practice is that a
clinician is well justified to approach primary prevention of peri-
odontitis or treatment of mild periodontitis with localized moderate
disease with the incorrect assumptions and expectations noted
above because our evidence indicates that most of the patients
who dentists see are unlikely to progress to more severe periodon-
titis and complications, regardless of whether or not they are trea-
ted more intensively. It makes sense for us to alter our current
approach to primary periodontitis prevention and treatment of mild
disease only if we can do 2 things: (i) use tools which reliably
increase the probability that we can identify an individual patient
who is more likely to be on the gray path than the blue path; and
(ii) obtain evidence that a different approach to prevention or early
treatment would make a difference to the individuals on the gray
path in terms of reducing the severity and complications of
periodontitis.
Axelsson et al90,91 randomly identified 50-year-old subjects in
the Swedish county of Varmland and performed comprehensive oral
examinations at baseline and 10 years later. By report, Axelsson
noted that more than 95% of the subjects had regular preventive
dental care at needs-related intervals. As a result of relatively good
preventive care during the 10-year period, the mean tooth loss per
subject per 10 years was <0.4 teeth, and those patients who lost 2
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or more teeth from clinically confirmed periodontitis were identified.
At the 10-year examination, buccal swab samples were collected for
interleukin-1 genetic analysis. Using 2 risk factors—smoking and
interleukin-1 genotype positivity92—individual patients were strati-
fied by 0, 1, or 2 risk factors, as shown in Figure 7, and analyzed for
frequency of patients losing 2 or more teeth from periodontitis.
Guided by Axelsson’s findings, a periodontitis prevention study
was designed, asking the following questions: “In dental patients
with no prior diagnosis of periodontitis and none of 3 previously val-
idated risk factors, do 2 professional cleanings each year lead to less
tooth loss compared with 1 cleaning annually?”21; and “In patients
with predefined risk factors do those with 2 cleanings annually have
a lower frequency of tooth loss than those with 1 cleaning annu-
ally?”
The clinical validity relative to assignment of individual risk for
periodontitis may be assessed by demonstrating that risk stratifica-
tion of individual patients leads to different outcomes. Important
outcomes relative to chronic periodontitis include disease progres-
sion, development of complications such as tooth loss, progression
following treatment, and impact on selected systemic diseases. As
discussed above, risk stratification clinical utility indicates that the
risk information can guide specific clinical prevention plans that
are more likely to lead to a difference in disease outcomes than
managing all patients as if they have the same susceptibility to
disease progression. In this study, the predefined specific interven-
tions were 1 or 2 clinical examinations and prophylaxes annually
in dental patients with no history of periodontitis (Figure 8).
As it is not practical to ask the above questions in a randomized
controlled clinical trial for more than 10 years in patients undergoing
different frequencies of preventive dental care, the investigators
adopted the experimental principles recommended for the study and
regulatory submission of biomarker performance evidence in previ-
ously collected large databases.55 Study inclusion criteria, end points,
and risk stratification criteria were predefined (Table 1). This was a
clinical utility study of a predefined risk assessment tool (ie, presence
of any of 3 risk factors constituted increased risk for tooth loss, and
such patients were designated “high risk.” The study was designed
and powered based on the primary clinical utility question. The study
was not intended or powered to assess end-point associations with
any single risk factor. The primary clinical utility question was
approached as one would for any new technology of potential clini-
cal value. The primary question therefore involves a simple calcula-
tion of frequency of low-risk patients with tooth loss during the
monitoring period of 16 years, depending on whether their preven-
tive regime consisted of 1 cleaning per year or 2 cleanings per year
(Table 2).
In this population of adults there appears to be a background
level of tooth loss of 14%-15% that is not reduced by regular and
consistent prophylaxes twice yearly for 16 years, even in patients
with none of the 3 risk factors. Some of the tooth loss that does not
appear to be reduced by regular preventive care may be attributable
to conditions such as root or crown fractures that do not benefit
directly from dental prophylaxes. In addition, in patients with any 1
of the 3 prespecified risk factors, 2 cleanings annually reduced tooth
loss comparable with the patients who had none of the risk factors.
In patients with 2 or 3 of the risk factors, 2 cleanings annually do
not appear to be sufficient to reduce tooth loss to the level seen in
patients with none or 1 risk factor.
F IGURE 6 Given current knowledge of the epidemiology of periodontitis severity and extent in the USA, we can postulate 3 curves of
periodontitis severity according to age of subject. One of those curves (green) represents individuals with minimal to no periodontitis through
middle age9 but who will probably develop mild to localized moderate periodontitis in later years.121 The blue line represents individuals who
will have mild disease and, with appropriate preventive care, will develop predominantly mild periodontitis with a few localized sites with
moderate disease. The gray line is intended to represent the 8%-10% of individuals who are on a different path. Time point X and Y
identifying two patients with the same periodontitis severity, but X identifies a patient who should be monitored more closely than Y patient
because patient X developed clinical disease at an earlier age
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Can we today identify individual risk for periodontitis? Evidence
supports that for adults without a clinical diagnosis of periodontitis,
patients can be objectively stratified into 2 or 3 risk categories that
differentiate clinical responses to different frequencies of preventive
care administered in clinical practice by general dentists and hygien-
ists. In this context, a risk profile defined by 3 risk factors appeared
to add value to clinical assessments by the patients’ own dentists.
5.1 | Clinical Scenario 3: guide treatment and
monitoring of periodontitis and secondary prevention
One of the objectives of applying precision medicine to periodon-
titis is to be able to identify patients with periodontitis who may
benefit from more intensive therapy during the primary treatment
of their periodontitis or during their maintenance care. More
intensive therapy may include more intensive bacterial control
using systemic or local antimicrobials and/or more frequent main-
tenance care. Furthermore, more intensive therapy may also
include enhanced efforts to control risk factors more effectively,
such as control of type 2 diabetes and more direct control of
inflammation through prescription of drugs93,94 or by nutritional
approaches.95
Do we have evidence that individual risk assessment adds value
to guide treatment and secondary prevention for patients with peri-
odontitis who are under the routine care of dentists or periodon-
tists?
There are multiple retrospective studies of various risk factors
relative to outcomes of periodontal active treatment and mainte-
nance care.13-16,18,96 These studies were small in size and did not
assign a composite risk to each individual patient and then quantify
F IGURE 7 Ten-year follow-up in randomly selected 50-year-old individuals from one county in Sweden. Most individuals had regular
preventive care with their dentist during the 10 years after the initial clinical assessment. The follow-up clinical examinations were used to
identify periodontal changes in a well-maintained adult population. In addition, the frequency of patients who lost 2 or more teeth from
clinically confirmed periodontitis were calculated based on 2 predefined risk factors: smoking and interleukin-1 (IL-1) genotype. 1Percentage
this risk group represented in the total sample (n = 276). 2P = .0016, Fisher’s exact test.90,91 Smokers were current smokers at baseline.
Positive (POS) or negative (NEG) status for IL-1 genotype was predefined as described previously21
F IGURE 8 Patient stratifications in the Michigan Personalized Prevention Study.21 The study outcomes were frequency of patients in each
group who lost teeth during the 16 years of claims history. IL-1, interleukin-1
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outcomes of treatment based on the individual risk calculated. There
was no clear approach to reduce bias. For example, patients with
infrequent compliance with maintenance care may have poorer
health habits overall compared with those who attend maintenance
visits on a regular frequency. These studies provide good preliminary
evidence to guide design of a definitive study of individualized risk
for periodontitis and outcomes of treatment. No previous studies
have looked at periodontitis treatment outcomes, specifically to
compare individualized risk with outcomes of different therapies.
5.2 | Clinical Scenario 4: guide periodontal
treatment to assist prevention and management of
certain systemic diseases
Substantial evidence supports an independent influence of peri-
odontitis on certain systemic diseases, including type 2 diabetes,
stroke, and coronary artery disease.97-101 The associations
between periodontitis and adverse pregnancy outcomes and
development/progression of rheumatoid arthritis appear to relate
directly to the effects of specific oral bacteria, which may be chal-
lenging to study relative to the effect of preventing or treating
periodontitis .102-105
A very different goal for identifying an individual’s risk for peri-
odontitis may be to reduce the likelihood that their periodontitis
influences that patient’s systemic health. This statement assumes
that the systemic influence of periodontitis is not a simple function
of the clinical severity of an individual’s periodontitis; however, the
evidence for that conclusion is very limited.
Is there evidence that individual risk assessments add value to
guide periodontitis treatment to prevent systemic implications of the
periodontitis or improve systemic disease?
The practical question is if, for patients with moderate-to-severe
generalized periodontitis, there is a way to risk-stratify the patients
to identify those who would be likely to benefit from more intensive
treatment and monitoring to reduce risk for certain systemic dis-
eases and their complications. And is there any evidence that some
patients with mild-to-localized moderate periodontitis can be risk
stratified to guide more intensive treatment and monitoring to
reduce the risk for certain systemic diseases?
6 | WHAT POTENTIAL MECHANISMS
MOST PLAUSIBLY EXPLAIN THE
ASSOCIATION OF PERIODONTITIS WITH
OTHER SYSTEMIC DISEASES?
When periodontitis is present, 2 intertwined general mechanisms—
inflammation and direct bacterial action—can theoretically activate
disease-implicated pathways in various tissues that are distant to
the periodontium. One mechanism involves activation of acute
phase proteins in the liver which initially help to amplify systemic
inflammatory components that broaden protection against the bac-
terial challenge. The acute phase proteins, such as C-reactive pro-
tein, can be activated by components from bacteria in the
periodontal pocket gaining access to the bloodstream through the
pocket epithelium and reaching and activating hepatocytes. In addi-
tion, inflammatory mediators in gingival tissue may enter the circu-
lation and activate the acute phase response. The inflammatory
mediators activated in the liver may lead to tissue damage if not
switched to a repair mode. Separately, with untreated moderate-to-
severe periodontitis, periodontal bacteria may enter the blood-
stream through the pocket wall and potentially localize to damaged
tissues, such as denuded vascular endothelium. One could specu-
late that moderate-to-severe periodontitis is likely to activate both
systemic inflammation directly and also seed periodontal bacteria
into the circulation.
Inflammation in an individual’s finger, whether activated by a bac-
terial infection or trauma, can activate the acute phase response in the
liver by means of circulating cytokines produced at the initial site of
inflammation. Periodontitis activates production and release of acute
phase proteins from the liver, with C-reactive protein being the most
TABLE 1 Description of the Michigan Personalized Prevention
Study21
1. Potential subjects were selected from a large anonymized dental
insurance claims database (Delta Dental of Michigan) guided by pre-
defined criteria. Entrance criteria were previously reported,21 with
some of the key criteria for participation as follows:
a. Age 35-57 years at first dental insurance claim
b. No history of periodontitis, based on dental claims data
c. Have employer-based dental insurance through same employer
and payor for more than 15 years
d. Dental insurance for individuals without periodontitis covered
the cost of 2 examinations and dental prophylaxes annually
e. Patients attended their dentist of choice consistently for either
1 or 2 dental prophylaxes every year for more than 15 years.
Criteria for patients with consistent attendance for 1 prophy-
laxis annually for 16 consecutive years, or consistent atten-
dance for 2 annually, are described in the manuscript 21
2. 25,452 patients met all criteria for inclusion and were invited to par-
ticipate, which included consent to access dental insurance claims,
consent for specified genetic analysis and submission of a DNA sam-
ple, and a medical history. 5117 patients agreed to participate and all
data were complete
3. All entered patients were classified as either “low risk” or “high risk,”
based only on predefined criteria
a. Low risk: none of 3 predefined risk factors: smoking, type 2 dia-
betes, positive for interleukin-1 genetic variations previously
shown to be proinflammatory and associated with severe or
progressive periodontitis
b. High risk: positive for any 1 of the 3 predefined risk factors:
smoking, type 2 diabetes, interleukin-1 genetic variations
4. Smoking history and diabetes history were collected by patient
responses to questionnaires
5. No effort was made to assess the quality of professional cleanings
because the study involved several-hundred general dentist offices
6. Primary endpoint for analysis was frequency of patients in each risk
group with tooth loss during the 16-year monitoring period
7. Primary question: In patients classified as low risk based on having
none of the specified 3 risk factors, did 2 cleanings annually reduce
tooth loss compared with 1 cleaning annually?
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well documented acute phase protein. The level of C-reactive protein
is higher in blood in individuals with periodontitis (P = .001) and the
C-reactive protein level is associated with the number of periodontally
active sites.106 The more severe and more generalized the periodonti-
tis case, the greater the association with increased C-reactive pro-
tein.107,108 Patients with severe periodontitis are more likely to have
C-reactive protein levels of ≥3 mg/L, which is associated with sub-
stantial increased risk of cardiovascular diseases.109 Depending on the
severity of the periodontitis and bleeding on probing, sites with more
disease have higher periodontal inflamed surface area scores .110
Based on available evidence, it is reasonable to expect that patients
with untreated or inadequately treated moderate-to-severe periodon-
titis will be more likely to have elevated C-reactive protein levels and
more bacteremias involving periodontal bacteria. In addition, recent
evidence indicates that higher periodontal inflamed surface area
scores are associated with higher medical costs.111
Periodontitis is certainly not the only chronic inflammatory
disease associated with increased frequency and severity of
other systemic diseases. Several chronic inflammatory diseases
that have no direct bacterial component increase blood levels of
C-reactive protein and are associated with increased prevalence
of certain systemic diseases. Investigators recently used the
large UK Clinical Practice Research Datalink to test the role that
“systemic inflammatory burden” may play in the initiation of
coronary artery disease, stroke, and type 2 diabetes112 (Fig-
ure 9).
Several important conclusions can be drawn from the results of
this study of chronic inflammation and systemic inflammatory bur-
den. It is clear that certain chronic inflammatory diseases, but not all,
increase the risk for type 2 diabetes, coronary artery disease, or
strokes. Severity of chronic inflammatory disease appears to be
important relative to risk for other diseases, and increased risk for
TABLE 2 Role of individualized patient risk and frequency of cleanings relative to observed frequency of long-term tooth loss in patients
without a history of periodontitis, as reported in the Michigan Personalized Prevention Study21







Any 1 risk factor
n = 2165










2 0.14 0.17 0.15 23
Frequency of patients in the designated risk group who lost 1 or more teeth during the 16 years of dental claims history.
aIn low risk individuals (none of 3 risk factors), 2 prophylaxes per year was not superior to 1 prophylaxis per year (P = .092).
bIn high risk individuals (1 or more of 3 risk factors), 2 prophylaxes per year was superior to 1 prophylaxis per year (P = .002).
cIn high risk individuals with any 1 of 3 risk factors, 2 prophylaxes per year was superior to 1 prophylaxis per year (P = .007).
dIn high risk individuals with any 2 risk factors or all 3 risk factors, 2 prophylaxes per year was not superior to 1 prophylaxis per year (P = .108).
F IGURE 9 Individuals with a prior diagnosis of specific chronic inflammatory diseases were identified in the UK Clinical Practice Research
Datalink and were compared by means of a matched cohort study with individuals with no prior diagnosis of any of the listed chronic inflammatory
diseases. The study endpoints were frequency of type 2 diabetes, stroke, or coronary artery disease, in a specific chronic inflammatory disease,
such as bullous skin disease, compared with the frequencies in the matched control group of none of the chronic inflammatory diseases.112
***P = .001; **P < .01; *P < .05
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one of the target diseases did not necessarily translate into risk for
other target diseases.
Although the evidence is strong for an independent influence of
periodontitis on certain systemic diseases, we should not assume
that we have sufficient understanding of the biologic roles that peri-
odontitis may play to design a successful intervention study.
It may be that periodontitis of a certain clinical severity has such
a strong impact on a systemic disease, like type 2 diabetes, that
intensive treatment of periodontitis will have a predictable effect on
type 2 diabetes outcomes. It is also possible that intervention in one
complex disease, such as periodontitis, may have a range of varia-
tions in the target complex disease, such as type 2 diabetes, and give
variable outcomes.
Fortunately, studies are in progress by multiple groups to explore
the complexity of periodontitis at the level of stratifying individual
patients by risk for influencing other systemic diseases. For example,
severe periodontitis, as defined by clinical measurements, was asso-
ciated with fasting plasma glucose level as an indication of risk for
diabetes. The investigators reported, as shown in Figure 10, that the
significant relationship between severe periodontitis and fasting
plasma glucose levels was conditional on the patient also having
blood C-reactive protein levels of greater than 3 mg/L.113
Exploration of the potential health benefits of controlling peri-
odontitis requires studies that stratify patients by multiple risk fac-
tors to guide intervention and assess outcomes of targeted systemic
diseases. Such work is in progress, as has been reported recently
and is summarized in Figure 11.114
7 | HOW CAN WE START TO UNRAVEL
RISK PROFILES THAT AUGMENT THE
INFLUENCE OF PERIODONTITIS ON
SYSTEMIC DISEASES?
One of our primary goals in exploring risk profiles is to help guide the
use of periodontitis prevention and treatment to enhance manage-
ment of certain systemic diseases. Evidence appears to support a role
for periodontal bacteria in adverse pregnancy outcomes.105,115-119
F IGURE 10 Increased severity of
periodontitis as represented by quartile of
probing depth was associated with
increased risk of type 2 diabetes mellitus
(T2DM) as assessed by fasting plasma
glucose levels ≥126 mg/dL or a prior
diagnosis of diabetes. The association was
only present in individuals who also had
elevated C-reactive protein (CRP) levels of
> 3 mg/L.113 Data were drawn from
NHANES III (n = 5731; age > 20 years).
Figure reproduced with permission from
the Journal of Periodontology.113 PD,
probing depth
• 5297 periodons paents treated 
in periodontal clinic
• Treatment:
• Oral hygiene instrucon
• Nonsurgical treatment phase
• Re-evaluaon 
• Residual pockets rescaled or surgically treated 
• Maintenance program
• 1 yr evaluaon aer acve 
treatment: “Poor responder” if 
• >10% residual pockets > 4mm, AND
• >20% sites with bleeding on probing
86.2
13.8
Treatment responder frequency and 
incidence of cardiovascular disease 








Incidence of CVD 15.3% 
Events
P < 0.001
F IGURE 11 Periodontitis patients who were treated in a specialist clinic but did not respond predictably to standard periodontal therapy
and maintenance care had a higher incidence of cardiovascular disease (CVD) events in long-term follow-up (median, 16.8 years). Events
included myocardial infarction, stroke, and heart failure 114
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For practical reasons, this discussion therefore will focus on the
potential role of risk factors that influence systemic inflammation as a
potential component of the periodontitis influence on certain sys-
temic diseases. The emphasis on systemic inflammation is not to mini-
mize the role of the microbiome in the potential periodontal risk for
systemic diseases but merely to allow some focus to the discussion.
Others can make a very coherent argument for taking a different
approach, and this is likely to be well justified given our early stage of
development.
The goal is to target, more precisely, the periodontal patients
who are more likely to benefit from more intensive periodontal dis-
ease prevention and management.
There appear to be some dominant concepts as to how risk
stratification may be important in assessing an individual periodontal
patient’s influence on specific systemic diseases.
• Concept 1: Periodontitis severity and extent of disease tells the
entire story. Other factors may be involved but do not add value
beyond periodontitis severity in planning to enhance management
of, for example, type 2 diabetes, through more intensive treat-
ment of periodontitis.
• Concept 2: Common risk factors, such as smoking, that are
known to influence both periodontitis and coronary artery dis-
ease, independently add to or amplify the risk for systemic dis-
ease that is attributable to periodontitis alone. This does not
discount the importance of periodontitis in the systemic risk but
suggests that incorporating the smoking status in a risk profile
adds value in planning the treatment of periodontitis for the pur-
pose of helping to control risk for atherosclerotic cardiovascular
disease events.
• Concept 3: It is a simple systemic inflammatory burden story. Peri-
odontitis is probably an important component of the chronic sys-
temic inflammatory burden that has been implicated in terms of
risk for chronic diseases and their complications. The risk profile
relative to guiding better management of chronic systemic disease
may depend on integrating multiple factors that alter the inflamma-
tory burden and may require control of multiple components in
order to influence the systemic disease in question.
Concept 2 and Concept 3 above have some overlap but lead
to different approaches to clinical action. Concept 1, if supported
by strong evidence, may allow the periodontist to play an impor-
tant role in control of chronic diseases; however, if Concept 3 is
correct the periodontist is likely to become more integrated in
health care.
Although periodontitis has a strong independent association with
selected systemic diseases, most clearly uncontrolled type 2 dia-
betes, coronary artery disease, strokes, rheumatoid arthritis, and
adverse pregnancy outcomes, the controlled intervention studies
that have been undertaken have been generally promising in type 2
diabetes, with some inconsistency that suggests a lack of clear pro-
tocol or limited knowledge of relevant disease factors. The
intervention studies in adverse pregnancy outcomes have not been
rewarding.
8 | CONCLUSIONS
Individualizing risk of periodontitis is not, in my opinion, simply an
interesting academic exercise, but perhaps an essential require-
ment to move the field of periodontitis forward.120 As a result of
great innovations and efforts by investigators and clinicians
throughout the world, we have made enormous advances in our
knowledge but now must move beyond retrospective observations
and associations. Stratification of patients in short-term challenge
models and in long-term intervention trials are perhaps the only
ways to move forward in a process that may differentiate the
value of periodontal specialist care. We must identify the complex
cases that require different preventive and treatment protocols to
demonstrate value in controlling local oral complications of peri-
odontitis and value in assisting the management of chronic sys-
temic diseases.
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